These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28081671)

  • 61. Epidemic meningitis control in countries of the African meningitis belt, 2016.
    Wkly Epidemiol Rec; 2017 Mar; 92(13):145-54. PubMed ID: 28361528
    [No Abstract]   [Full Text] [Related]  

  • 62. The Meningitis Vaccine Project.
    LaForce FM; Konde K; Viviani S; Préziosi MP
    Vaccine; 2007 Sep; 25 Suppl 1():A97-100. PubMed ID: 17521780
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Meningococcal disease control in countries of the African meningitis belt, 2014.
    Wkly Epidemiol Rec; 2015 Mar; 90(13):123-31. PubMed ID: 25816448
    [No Abstract]   [Full Text] [Related]  

  • 64. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.
    Pajon R; Fergus AM; Koeberling O; Caugant DA; Granoff DM
    PLoS Negl Trop Dis; 2011 Sep; 5(9):e1302. PubMed ID: 21909444
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Meningococcal carriage in the African meningitis belt.
    Trotter CL; Greenwood BM
    Lancet Infect Dis; 2007 Dec; 7(12):797-803. PubMed ID: 18045562
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine.
    LaForce FM; Okwo-Bele JM
    Health Aff (Millwood); 2011 Jun; 30(6):1049-57. PubMed ID: 21653956
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data.
    Trotter CL; Lingani C; Fernandez K; Cooper LV; Bita A; Tevi-Benissan C; Ronveaux O; Préziosi MP; Stuart JM
    Lancet Infect Dis; 2017 Aug; 17(8):867-872. PubMed ID: 28545721
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Control of epidemic meningococcal meningitis by mass vaccination. I. Further epidemiological evaluation of groups A and C vaccines in northern Nigeria.
    Mohammed I; Obineche EN; Onyemelukwe GC; Zaruba K
    J Infect; 1984 Sep; 9(2):190-6. PubMed ID: 6438244
    [TBL] [Abstract][Full Text] [Related]  

  • 69. An overview of bacterial meningitis epidemics in Africa from 1928 to 2018 with a focus on epidemics "outside-the-belt".
    Mazamay S; Guégan JF; Diallo N; Bompangue D; Bokabo E; Muyembe JJ; Taty N; Vita TP; Broutin H
    BMC Infect Dis; 2021 Sep; 21(1):1027. PubMed ID: 34592937
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Phylogenetic relationships and regional spread of meningococcal strains in the meningitis belt, 2011-2016.
    Topaz N; Caugant DA; Taha MK; Brynildsrud OB; Debech N; Hong E; Deghmane AE; Ouédraogo R; Ousmane S; Gamougame K; Njanpop-Lafourcade BM; Diarra S; Fox LM; Wang X
    EBioMedicine; 2019 Mar; 41():488-496. PubMed ID: 30846392
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa.
    Pajon R; Fergus AM; Granoff DM
    PLoS One; 2013; 8(6):e66536. PubMed ID: 23805230
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.
    Soriano-Gabarró M; Rosenstein N; LaForce FM
    J Health Popul Nutr; 2004 Sep; 22(3):275-85. PubMed ID: 15609780
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Epidemiological and control aspects of meningococcal meningitis epidemics in Africa].
    Spiegel A; Moren A; Varaine F; Baudon D; Rey M
    Sante; 1994; 4(3):231-6. PubMed ID: 7921694
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM).
    Frasch CE; Preziosi MP; LaForce FM
    Hum Vaccin Immunother; 2012 Jun; 8(6):715-24. PubMed ID: 22495119
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014.
    Djingarey MH; Diomandé FV; Barry R; Kandolo D; Shirehwa F; Lingani C; Novak RT; Tevi-Benissan C; Perea W; Preziosi MP; LaForce FM
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S434-41. PubMed ID: 26553672
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac.
    Kristiansen PA; Ba AK; Ouédraogo AS; Sanou I; Ouédraogo R; Sangaré L; Diomandé F; Kandolo D; Saga IM; Misegades L; Clark TA; Préziosi MP; Caugant DA
    BMC Infect Dis; 2014 Dec; 14():663. PubMed ID: 25472422
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Response Strategies against Meningitis Epidemics after Elimination of Serogroup A Meningococci, Niger.
    Maïnassara HB; Paireau J; Idi I; Pelat JP; Oukem-Boyer OO; Fontanet A; Mueller JE
    Emerg Infect Dis; 2015 Aug; 21(8):1322-9. PubMed ID: 26196461
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Conjugate vaccine introduction in the African meningitis belt: meeting surveillance objectives.
    Mueller JE
    Trop Med Int Health; 2013 Jan; 18(1):58-64. PubMed ID: 23121399
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Neisseria meningitidis and meningitis].
    Nicolas P; Debonne JM; Martet G
    Med Trop (Mars); 1999; 59(1):68-78. PubMed ID: 10472587
    [TBL] [Abstract][Full Text] [Related]  

  • 80. An Update on Meningococcal Vaccination.
    Garland JM
    R I Med J (2013); 2020 Aug; 103(6):41-43. PubMed ID: 32752565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.